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Flow cytometryPancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease, unusually resistant against
therapy. It is generally felt that stratification of patients for personalized medicine is the way forward.
Here, we report that a subpopulation of PDACs shows strong activation of the mTOR signaling cassette.
Moreover, we show that inhibition of mTOR in pancreatic cancer cell lines showing high levels of mTOR
signaling is associated with cancer cell death. Finally, we show using fine needle biopsies the existence of
a subpopulation of PDAC patients with high activation of the mTOR signaling cassette and provide evi-
dence that inhibition of mTOR might be clinically useful for this group. Thus, our results define an unrec-
ognized subpopulation of PDACs, characterized by high activation of mTOR and show that identification
of this specific patient group in the early phase of diagnosis is feasible.
 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading
cause of cancer related death in the world and more than
260,000 people die of this disease every year worldwide [1].
Due to local invasion of vasculature or distant metastasis, only
15–20% of patients are surgical candidates at presentation. Of
those operated, the 5-year survival is only 10–15% and adjuvant
therapy only improves disease free survival from 5.5% to 16.5%
at 5 years but has no impact on survival [2]. The median sur-
vival after diagnosis of locally advanced unresectable disease
is 4–6 months, and 2–4 months for patients presenting with
metastatic disease [3,4]. PDAC is among the most chemoresis-
tant cancers and advancements in traditional chemotherapeu-
tics have been especially disappointing as many targeted
therapies have failed to show any benefit. Current palliative
therapy is limited to patients with optimal performance score(WHO 0-1) with only 4 months survival benefit in patients with
metastatic disease (FOLFIRINOX) [5]. Research efforts are fo-
cused on early detection, and multimodality treatment with sur-
gery and chemoradiation. Personalized medicine-based therapy
might be another approach to achieve significant long term
benefit in patients with PDAC [6].
PDAC is a heterogeneous disease with different pathways af-
fected in different patients. Next generation sequencing and micro-
array analysis have revealed a set of 12 core cellular signaling
pathways and processes that were genetically altered in 67–100%
of PDAC tumors. These genetic alterations involve pathways such
as apoptosis, KRAS, Hedgehog, WNT/Notch, TGF-beta, and DNA re-
pair pathways [7]. Mutations in the KRAS gene along with activa-
tion of EGFR and loss of telomeres are required for the initiation
of PDAC [8–10]. The progression of PDAC requires the constitutive
activation of Ras/mammalian target of Rapamycin (mTOR) or Ras/
MEK/ERK pathways [11–13]. In PDAC, levels of phospho S6 (pS6),
the activated form of a downstream protein of the mTOR pathway
involved in translation initiation, are markedly increased [14–16].
Moreover, mTOR pathway activation is shown in pancreatic cancer
cell lines, tumor xenografts, human pancreatic tumors, and in a
number of other human tumors [17–19]. Previous studies have
shownmTOR pathway activation in PDACs, approximated between
25% and 75% [14,19]. The mTOR pathway consists of two protein
complexes, in which mTOR, raptor and mLST8 proteins constitute
to form the mTOR Complex 1 (mTORC1) and mTOR, rictor and
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growth and associated proliferation, mTORC1 plays a vital role by
integrating signals from nutrients and energy status. It regulates
several processes like ribosome biogenesis, protein synthesis,
metabolism and autophagy [20]. mTORC2 plays a role in cytoskel-
etal organization through protein kinase C and paxillin [21]. Rapa-
mycin, and its synthetic derivatives (rapalogs), can inhibit the
mTOR pathway by binding to FK-binding protein-12, which in turn
binds to the mTOR protein, and subsequently preventing the
assembly of mTORC1 [22]. Prolonged use of rapalogs has shown
to disrupt mTORC2 as well [23]. Several clinical trials involving
rapalogs showed clinical benefit in only a minority of pancreatic
cancer patients, however none of the studies involved a sensitivity
assay of the tumor to rapamycin or rapalogs [17,24]. In view of the
molecular heterogeneity of PDAC, the activity of the Ras/mTOR
pathway, and incidental benefit of rapalog treatment in PDAC,
we hypothesize that a subpopulation of PDAC patients sensitive
for rapalog treatment could be identified using ex vivo biopsies.
Hence, the mTOR axis can be a promising target to be included
in treatment protocols for PDAC using rapamycin or rapalogs in a
subpopulation of patients.2. Material and methods
2.1. Cell lines
Pancreatic cancer cell lines BxPC3, Su86.86, HPAF, and HS700T were cultured as
confluent monolayers in RPMI-1640 (Gibco) with penicillin and streptomycin
(invitrogen) and 7.5% Fetal Calf Serum (FCS) (Sigma–Aldrich) using routine proce-
dures (5% CO2, at 37 C). Capan-1 was cultured using IMDM (Gibco) supplemented
with 20% FCS. The cell lines were a kind gift of the department of surgery of the
Erasmus MC. The cell lines were authenticated by means of a STR-analysis.2.2. Patients and specimens
Appropriate ethical approval was obtained for all procedures involving patients
or patient material. We included 64 slides of 39 formalin fixed paraffin embedded
(FFPE) specimens from pancreatic surgery with a histologically confirmed PDAC or
neuroendocrine tumor. The tissue blocks were collected from a prospectively main-
tained pathology tissue bank at the Erasmus MC. Specimens were sectioned at 5 lm
(Microm HM325 Microtome), incubated at 37 C overnight, and stored until used
for immunohistochemistry staining.
Endoscopic ultrasound guided fine needle aspiration biopsies (EUS-FNABs)
were obtained from patients suspected for pancreatic cancer (or with a pancreatic
mass lesion). All patients provided written informed consent. The EUS-FNABs were
obtained from the endoscopy department and transported to the laboratory in
RPMI-1640 medium with 10% FCS. The biopsy was washed three times with PBS
containing penicillin and streptomycin (Invitrogen). Single cell suspensions were
prepared using 0.5 mg/ml collagenase IV (Sigma–Aldrich) and pushed through a
100 lm cell strainer (BD Falcon). The cells were suspended in RPMI-1640 (Gibco)
and counted using a slide with counting grids (Kova Glasstic Slide 10, Hycor Bio-
medical Ltd., Penicuik, UK).2.3. Immunohistochemistry
Tissue sections were deparaffinized in xylene for 5 min and rehydrated using
ethanol. The endogenous peroxidase activity was blocked with methanol and 3%
H2O2 followed by tap water immersion for 5 min. Antigen retrieval was performed
by boiling in preheated buffer 10 mM citrate buffer pH 7.6 for 10 min at 200W in a
microwave. Next, slides were blocked by 10% goat serum in phosphate-buffered sal-
ine tween pH 7.4 for 1 h at room temperature. Primary antibodies rabbit monoclo-
nal anti-pS6 (1:250, Cell Signaling Technology, Beverly, MA, USA) was added and
incubated at 4 C overnight. Envision goat anti-rabbit-horseradish peroxidase
(DAKO, Denmark) was used as secondary antibody [25]. WKU and VN scored the
slides independently in a blinded manner. Five high power fields were counted
for each slide. The percentage of cells that stained positive (immunoreactivity above
background) in the area was quantified. The pS6 level was scored as follows: a score
of 0 for less than 3%, a score of 1 between 3% and 10%, a score of 2 between 10% and
50%, and a score of 3 for more than 50% of positively stained cells (scoring system
developed by KB). Pictures were taken using the Zeiss Axioskop20 microscope, Ni-
kon Digital Sight DS-U1 camera and NIS-Elements 3.00 program.2.4. Cell viability assay
To assess the effect of rapamycin on pancreatic cancer cell lines we used a MTT-
assay. In short, 10,000 cells from each cell line were incubated with 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The purple formazan is
measured at 490 nm and 595 nm using a microplate reader (Model 680XR Bio-
Rad) at 72 h. The functional viability of cells was calculated using the mean OD in
sample well divided by the mean OD in the control well  100%. To show the cor-
relation of increasing concentration of rapamycin with cytotoxicity in pancreatic
cancer, we used a linear regression to reject the null hypothesis where changes in
rapamycin concentration are not associated with increased cell death. The p-value
is considered significant when p < 0.01.2.5. Western blot
Western blotting was performed according to standard fluorescent Odyssey
immunoblotting (Li-COR Biosciences, Lincoln, NE, USA). Antibodies specific for p-
S6 and light chain 3 (LC3A/B-I and II) (all 1:1000, Cell Signaling Technology) were
used. To ascertain equal loading and normalization of the protein for quantification,
beta-actin (1:2000, Santa Cruz) was used. The secondary antibodies used for detec-
tion were goat anti-rabbit and rabbit anti-mouse (1:5000, Li-COR Biosciences).
Transfer membranes were transferred to 50 ml sterile light-protecting centrifuge
tubes (Greiner bio-one), incubated with secondary antibodies and washed. Fluores-
cence Odyssey system (Li-COR Biosciences, Lincoln, NE, USA) was used to visualize
and quantify protein expression. Semi quantitative expression data were deter-
mined by Odyssey 3.0 software and normalized using beta-actin for reference gene
protein expression [25].2.6. Flow cytometry
To assess pS6 expression levels, we analyzed pancreatic cancer cell lines and
single cell suspensions prepared from EUS-FNABs as described above, using flow
cytometry.
The pancreatic cancer cell lines were washed with 0.1% sodium chloride (Sig-
ma–Aldrich) in PBS and trypsinized with 0.05% trypsin EDTA (Invitrogen). A mini-
mum of 100,000 cells were used for each assay. The cells were divided in the
following three conditions during 2 h: blank unstained cells, RPMI-1640 only (to
measure basal pS6 levels), and RPMI-1640 with 0.1 lM rapamycin (to measure
inhibition of pS6). The same conditions were applied to single cell suspensions from
EUS-FNABs.
Cell permeabilisation was done with a permeabilisation buffer (0.5% saponine,
1% FCS, 0.02% EDTA in PBS). The cells were stained using cytokeratin 8/18 mouse
mAb (CK8/18; 1:100; Cell Signaling Technology) and secondary labeled with anti-
Mouse IgG eFluor 660 (1:100; eBioscience, Ltd., UK) to mark epithelial cells.
CK8/18 has been shown to be expressed as much as 100% in PDAC [26]. Finally,
we stained the samples with V450 Mouse anti-pS6 (1:50; BD Biosciences, Breda,
Netherlands). Data was analyzed using FlowJo (v 7.6.5, Treestar, Ashland, OR). Mean
Fluorescence Intensity (MFI) was calculated using the geometric mean of the CK8/
18+population. Mean values were compared using a student T-test.3. Results
3.1. A subpopulation of PDACs is characterized by strong activation of
the mTOR signaling cassette
To study activation of the mTOR pathway in pancreatic cancer,
we performed an immunohistochemical staining of a set of FFPE
specimens that contains 42 normal acinar regions, 42 normal duc-
tal epithelium, 15 PanIN lesions, 7 neuroendocrine tumors, and 39
PDAC regions for the levels of pS6 (Fig. 1). The proportion of tissue
expressing pS6 is 50% in normal ducts, 67% in PanIN lesions, and
82% in adenocarcinoma regions (Fig. 1). Normal acinar regions
show high levels of pS6, while normal duct epithelium exhibits
much lower pS6 levels overall (Fig. 2A). Since it has been shown
that the mTOR pathway is deregulated in neuroendocrine tumors
(NET), we used NETs as positive controls [27] (Fig. 2B). Differences
in pS6 staining were observed between various patients with
PDAC, especially differential staining of dysplastic ducts and stro-
ma can be pronounced (compare Fig. 2C with Fig. 2D). The variabil-
ity in pS6 levels was also seen in various PanIN lesions
(Supplementary Figs. S1A and S1B). Thus, substantial variation in
the activation of mTOR pathway exists and our results demon-
strate the presence of a subgroup of pancreatic adenocarcinoma
Fig. 1. Graph presenting proportion of pS6 levels in various histological conditions.
Normal acinar regions were adjacent to PDAC regions. Normal duct represents the
fraction of positive ductal epithelium in normal regions. PanIN lesions were also
evaluated based on the positive staining of abnormal epithelium. The proportion of
samples staining positive for pS6 increases from normal ductal epithelium to PDAC.
NETs were used as positive control and had similar distribution to PDACs. The
scoring system is described in the materials and methods section.
Fig. 2A. Representative normal region adjacent of PDAC stained for pS6. Normal
duct epithelium (HD) score 0, which was found in 50% of the cases. Normal acinar
region (HA) score 3 (20).
Fig. 2B. Representative image of a pancreatic neuroendocrine tumor (NET), score 3
(10). NETs were stained as positive controls as it has been shown that activation of
the mTOR pathway, mediated by IGF-1, is necessary for proliferation in pancreatic
NETs [45].
Fig. 2C. Representative adenocarcinoma region, score 0 (10). Staining less than 3%
of the adenocarcinoma was observed.
Fig. 2D. Representative adenocarcinoma region, score 3 (10).
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ing cassette.3.2. Rapamycin-dependent cytotoxicity in pancreatic cancer cell lines
correlates with the level of mTOR-dependent signaling
A logical question arising from our discovery of a mTOR hyper-
activated subset of PDAC is whether cancer survival is dependent
on activation of this signaling cassette in such cancers. To this
end, we compared pancreatic cancer cell lines exhibiting different
levels of mTOR activation for their sensitivity to the mTOR inhibi-
tor. We determined pS6 levels in BxPC3, Su86.86, HS700T, HPAF,
and Capan-1 and its inhibition after 2, 6, and 18 h incubation with
0.1 lM rapamycin. BxPC3 and SU86.86 are most sensitive to rapa-
mycin with a decrease of pS6 expression up to 655 and 355-fold
(p < 0.01) in Western blot respectively (Fig. 3), and thus, display
most mTOR signaling activity. Rapamycin induced decrease of
pS6 expression was less pronounced in Capan-1, HPAF, and
HS700T cells, with up to a 10-fold decrease after 2 h (Fig. 3), and
therefore, these cell lines are characterized by a substantial lower
degree of rapamycin sensitivity. The level of rapamycin-sensitive
mTOR activity correlated well with the cytotoxic effects of rapamy-
cin. In BxPC3 (Fig. 4A) and SU86.86 (Fig. 4B) 12.5 nM rapamycin
decreases cell viability to 69%(±10.0%) and 75%(±4.0%), respec-
tively. In contrast, HS700T, HPAF, and Capan-1 pancreatic cancer
cells show much less pronounced mTOR activation. Accordingly,
Fig. 3. Western blot analysis and quantification of phosphorylated S6 in BxPC3, SU86.86, HS700T, HPAF, and Capan-1. The cell lines were exposed to increasing duration of
0.1 lM rapamycin. Lysates were subjected to pS6 antibodies and subsequently quantified and normalized against beta-actin. Higher basal expression of pS6 is seen in BxPC3
and SU86.86 compared to HS700T. In BxPC3, rapamycin inhibits phosphorylation of S6 by 30, 392, and 655-fold after 2, 6, and 18 h respectively with rapamycin. Similarly, in
SU86.86 this effect is 106, 132, and 355-fold in the same conditions. HS700T is less rapamycin-sensitive as seen by a less pronounced decrease of pS6 expression (11, 15, and
20-fold decrease). The inhibition of pS6 levels in HPAF and Capan-1 were also lower, exhibiting a 8, 17, and 29-fold decrease in HPAF, and a 8, 48, 82-fold decrease in Capan-1.
Experiment was performed in duplicate, one representative blot is shown.
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cin, exhibiting cell viabilities of 113.4%(±6.0%) and 131.4%(±18.4%)
at 200 nM concentration. HS700T cells shows 80.8%(±1.9%) cell via-
bility in the presence of 12.5 nM rapamycin and more than 50 nM
rapamycin is needed to obtain a comparable decrease in cell viabil-
ity as in BxPC3 cells (Fig. 4E). Thus, high activation of mTOR shows
a correlation with increased sensitivity to mTOR inhibition in pan-
creatic cancer. To illustrate the correlation between pS6 inhibition
and cell viability we plotted both parameters for all cell lines. The
mean pS6 inhibition after 2 h incubation with 0.1 lM rapamycin of
both responsive and non-responsive cell lines (derived from wes-
tern blot) was plotted against the percentage of cell viability as
measured by MTT-assay with the same concentration of rapamycin
(Fig. 5). Sensitivity to mTOR inhibition is correlated with decreased
cell viability for the rapamycin responsive cell lines but not for the
rapamycin unresponsive cell lines.
3.3. Rapamycin induces autophagy in rapamycin sensitive pancreatic
cancer cell lines
Subsequently, we were interested in the molecular mechanism
of cytotoxicity in mTOR-proficient pancreatic cancer cell lines. In
the canonical response to rapamycin, induction of autophagy and
apoptosis are considered the major effectors here. To assess the
role of autophagy and apoptosis in rapamycin induced decrease
of cell viability of pancreatic cancer cell lines, we performed Wes-
tern blot analysis on LC3A/B-I and II. The expression of LC3A/B-II
increased 2.4-fold in both BxPC3 and SU86.86, after 18 h incuba-
tion with rapamycin (Fig. 6). In contrast to BxPC3 and SU86.86,
we did not observe a significant increase of LC3A/B-II in HS700T,HPAF, or Capan-1 (Fig. 6). These results support a role for hyperac-
tivated mTOR for maintaining survival in a subpopulation of PDAC.
3.4. Sensitivity to rapamycin in pancreatic cancer cell lines can be
measured using flow cytometry
We have shown in Western blot that rapamycin reduces phos-
phorylation of S6 in pancreatic cancer cell lines. To translate this
into an ex vivo sensitivity assay, to a protocol useful for personal-
ized medicine in clinical practice, we measured phosphorylation
of S6 in pancreatic cancer cell lines using flow cytometry. Rapamy-
cin resulted in an absolute reduction of CK 8/18+pS6+cells by more
than 40% in BxPC3 (Fig. 7A) and SU86.86 (Supplementary Fig. S2).
In contrast, there was a minimal reduction of less than 1% within
the CK8/18+pS6+population in the rapamycin-unresponsive cell
lines; HS700T (Fig. 7B), Capan-1 (Supplementary Fig. S3A), and
HPAF (Supplementary Fig. S3B). We observed the same effect of
rapamycin on the amount of pS6 per cell as shown in Fig. 7C. Thus,
flow cytometry is in principle useful for determining the sensitivity
of pancreatic cancer cells to mTOR inhibition.
3.5. The mTOR pathway is activated in a subfraction of EUS-FNABs
from pancreatic cancer patients and is potently inhibited by
rapamycin
Finally, we determined ex vivo mTOR pathway activation in
biopsies obtained through endoscopic ultrasonography in patients
suspected for pancreatic cancer. Two hours of incubation with
0.1 lM rapamycin inhibited pS6 levels in CK8/18+cells in two out
of nine samples (22%). In those two samples we identified as
Fig. 4. Graphs depicting the effect of rapamycin on cell viability in pancreatic cancer cell lines. BxPC3 (A), SU86.86 (B), Capan-1 (C), HPAF (D), and HS700T (E) were treated
with increasing doses of rapamycin for 72 h. Mean values are averages from 3 independent experiments performed in triplicate.
Fig. 5. Scatter plot showing the correlation of pS6 levels and predicted cytotoxicity.
On the x-axis is the fold pS6 inhibition (retrieved from western blot with 2 h 0.1 lM
rapamycin) and cell viability on the y-axis (retrieved from MTT-assay with 0.1 lM
rapamycin). A non-linear regression curve was fitted through the available
datapoints indicating that higher inhibition of pS6 levels correlate with higher
rapamycin-dependent cytotoxicity. Responsive cell lines (BxPC3 and SU86.86) are
in the higher range of pS6 inhibition, corresponding with lower cell viabilities. In
contrast, lower pS6 inhibition in cell lines correspond to better survival of
pancreatic cancer cells (Capan-1 and HPAF). HS700T however, exhibit declining
cell viability without proper mTOR inhibition, most likely due to off-target effects.
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more than 90% (94.2% and 98.4%) in the amount of pS6 expressing
cells. Fig. 8 depicts two representative scatter plots and histograms
of a patient with high levels of pS6 and response to rapamycin
treatment (Fig. 8A) and a patient with no response to rapamycin(Fig. 8B). To measure the phosphorylation of S6 per cell, the pS6
MFI of CK8/18+cells was calculated. Potential responders (n = 2)
showed a mean reduction in MFI of 81.3% (±2.7%), while the aver-
age MFI change in non-responders (n = 7) was 8.8% (±6.1%)
(p < 0.01) (Fig. 8C). Thus, EUS-FNAB and flow cytometry are useful
for identifying potential responders to rapamycin therapy.4. Discussion
Our ex vivo analysis on EUS guided FNABs of patients shows that
22% of PDAC patients potentially benefits from treatment with rap-
alogs. This number is in accordance to what was observed in a pre-
clinical setting in mice, where rapamycin induced regression in 4
out of 17 xenografts (23.5%) [14]. However, the presence of feed-
back loops after mTOR inhibition can induce therapy resistance
in these patients [28]. Consequently, the question remains whether
these patients can be treated with rapalog monotherapy or
whether rapalog will be part of a treatment protocol. In the coming
years it will become clear whether strategies involving combina-
tion therapy with second generation mTOR inhibitors which inhi-
bit mTORC1 and mTORC2 [29], dual mTOR/PI3K inhibitors which
block the PI3K/Akt feedback activation [30], or the addition of
JAK2/STAT5 inhibitors [31] will prove beneficial in PDAC.
Pancreatic cancer is a heterogeneous disease, with various dif-
ferent mutations in individual genes among a diversity of path-
ways [7]. The idea of tumor heterogeneity in pancreatic cancer is
a concept that has been established decades ago [32]. In our immu-
nohistochemistry data we confirmed heterogeneity in terms of
Fig. 6. Western blot analysis and quantification of autophagy marker LC3A/B in BxPC3, SU86.86, HS700T, HPAF, and Capan-1. The cell lines were treated with increasing
duration of 0.1 lM rapamycin. Next, we prepared lysates and these were subjected to LC3A/B antibodies. The expression of LC3A/B-II increases during prolonged incubation
with rapamycin in rapamycin-sensitive cell lines. We quantified the expression of LC3A/B-II, normalized against beta-actin, as indicator of autophagy.
Fig. 7. Flow cytometry scatter plots and corresponding overlay histograms of a responsive cell line – BxPC3 (A) and a non-responsive cell line – HS700T (B). In accordance
with our western blot data, BxPC3 display higher basal mTOR activation in the CK8/18+population (64.0%). This CK8/18+pS6+population was effectively reduced after 2 h
incubation with 0.1 lM rapamycin to 11.1%. In contrast, basal mTOR activation in HS700T was markedly lower (3.48%) and the effect of rapamycin on the CK8/
18+pS6+population was therefore diminished. The overlay graphs are a representation of the count (y-axis), in the CK8/18+population (marked by the red box), within the
pS6-channel (x-axis).
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Fig. 7C. Graphical overview of the mean fluorescence intensity (MFI) of all cell lines
incubated with and without 0.1 lM rapamycin during 2 h. The MFI change in
rapamycin-sensitive cell lines was 57.7% and 51.9% for BxPC3 and SU86.86,
respectively. In HS700T the change in MFI was 0.8%. Capan-1 and HPAF exhibited
reductions of 9.8% and 13.0%, respectively. The MFI was calculated within the CK8/
18+population only.
Fig. 8C. Graph depicting changes in MFI in potential responders and non-
responders. Single cell suspensions from EUS-FNABs were measured using flow
cytometry. Each sample was incubated without and with 0.1 lM rapamycin for 2 h.
We selected the CK8/18+population and calculated the MFI in each condition. Two
samples displayed a substantial reduction in MFI by an average of 81.3%. Seven
samples were classified as non-responders due to the minimal change in MFI after
treatment with rapamycin.
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crease in mTOR activation from normal ducts, to PanIN lesion,
and finally in PDAC. This heterogeneity is also observed between
PDACs, which makes selection of patients necessary to avoid futile
treatment. Moreover, we also observed high mTOR activation in
normal acinar region. However, the normal acinar regions were ta-
ken adjacent to adenocarcinoma so it is debatable whether mor-
phological normal areas are actually normal, considering the yet
unknown origin of PDAC [33].
The data from the western blot and MTT-assay show increased
cytotoxicity in pancreatic cancer cell lines with hyperactivatedFig. 8. Representative flow cytometry scatter plots and corresponding overlay histogr
exhibited activation in the mTOR pathway which responded to rapamycin. The non-r
rapamycin. The overlay graphs are a representation of the count (y-axis), in the CK8/18mTOR pathway after the addition of rapamycin. Both responsive
cell lines (BxPC3 and SU86.86) show significant correlation of
increasing dose of rapamycin with cytotoxicity (p 6 0.001). In com-
parison, unresponsive cell lines do not show a clear threshold ef-
fect but rather a dose response effect as can be observed in
HS700T(most likely due to off-target effects). To further study
the mechanism behind increased cytotoxicity, we analyzed
autophagy (type 2 cell death) in our pancreatic cancer cell lines.
Interestingly, we observed that rapamycin only induced autophagy
in rapamycin sensitive pancreatic cancer cell lines. In contrast,ams of a potential responder (A) and non-responder (B). The potential responder
esponder showed no change in the CK8/18+pS6+population after treatment with
+population (marked by the red box), within the pS6-channel (x-axis).
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seem unsensitive to rapamycin, which is also reflected in a lower
degree of pS6 inhibition and failure to induce autophagy. Rapamy-
cin has been shown to induce autophagy pancreatic cancer cell
lines before [34]. In this context however, autophagy was most
likely activated due to the antitumor effect of rapamycin rather
than a protective response [34,35]. Whether autophagy in cancer
is a prosurvival process or part of antitumor effects is still point
of discussion. Yang et al. found that in the case of pancreatic can-
cer, autophagy is needed for tumorigenic growth [36]. Therefore,
they recommend trials in PDAC using drugs targeting autophagy,
such as chloroquine.
Using flow cytometry, we show that the responsiveness of a tu-
mor for rapamycin can be quantitatively assessed. Our pancreatic
cancer cell line data indicate that hyperactivation of the mTOR
pathway in PDAC can be potently inhibited by tolerable concentra-
tions of rapamycin. Hyperactivation of the mTOR pathway is also
seen in patients with the Peutz-Jeghers syndrome where muta-
tions in LKB1 can lead to inactivation of the LKB1/AMPK/TSC axis
and thereby activating mTORC1, and eventually leading to the
development of tumors [37]. Interestingly, 3–35% of PDACs have
been shown to have loss of LKB1 expression in multiple studies
[38,39] and most likely subsequent mTOR activation. To further
support the rationale of the use of mTOR inhibitors, Klümpen
et al. reported successful use of a rapalog (everolimus) in the treat-
ment of a patient with advanced pancreatic cancer suffering from
Peutz-Jeghers syndrome [40], supporting the need for individual-
ized treatment. The question remains how to obtain tumor sam-
ples for stratification, and we believe EUS guided FNAB could be
helpful in this situation. Phenotyping of these EUS-FNABs using
flow cytometry shows that the determination of rapamycin sensi-
tivity in clinical setting is possible, paving the way for personalized
medicine.
Our study has some limitations pertaining the translation into
an in vivo situation. We could not directly correlate our flow
cytometry data of EUS-FNABs with immunohistochemical staining
of the same samples due to insufficient material. Furthermore, in
our sensitivity assays of EUS-FNABs, we did not include measure-
ments of cell viability. Therefore, solely blocking the mTOR path-
way in a patient might not be sufficient to combat the tumor,
regardless of sensitivity towards rapamycin or rapalogs.
The results of our study suggest that it is possible to identify a
subpopulation of pancreatic cancer patients with mTOR activation
that are eligible for treatment with rapalogs. The lack of this test in
previous studies with rapalogs might be an explanation for the dis-
appointing results; only 20% would have been sensitive to rapalog
treatment. Similarly, some pancreatic cancer cell lines seem totally
resistant to mTOR inhibition, which may explain the failure of rap-
amycin therapy in unselected pancreatic cancer patients. Consis-
tent with previous literature, we found an activation of the
mTOR pathway in cell lines, resection specimens, and EUS-FNABs
of PDAC [19,41]. This activation in pancreatic cancer cell lines
and EUS-FNABs was effectively blocked by rapamycin in western
blot and flow cytometry analysis. Furthermore, inhibition of pS6
levels by rapamycin are a good predictor of later cytotoxicity of
the drug or its analogues. Targeting mTOR using rapalogs has re-
cently shown to be efficacious in several neoplastic diseases such
as pancreatic neuroendocrine tumors [42], hormone receptor posi-
tive breast cancer [43], and renal cell carcinoma after the failure of
treatment with sunitinib or sorafenib [44].
We conclude that tumor tissue obtained in a minimal invasive
way by means of endoscopic ultrasound guided fine-needle biopsy
in chemotherapy naive PDAC patients can be used ex vivo to iden-
tify a subpopulation of approximately 22% of patients that are
potentially responsive to rapalog treatment. Such selection of
patients for targeted treatment avoids futile treatment andpotentially improves the outcome of existing chemotherapeutic
regimens. Given our findings, future research should aim for com-
bining ex vivo drug sensitivity analysis using pS6 flow cytometry
analysis as biomarker for therapeutic effect with in vivo patient re-
sponses to therapy.Conflict of Interest
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